About this episode
In this episode of the Darshan Talks Podcast, host Darshan Kulkarni Pharm.D, MS, Esq. discuss 340B Pharmacy Programs with guest Rita Baskett. Rita Baskett RPh, MBA/MHA, CEO of Integrated Pharmacy Services, Inc. that is a consulting firm that concentrates on 340B solutions. The company focus on the integration of compliant pharmacy solutions to improve costs and health outcomes through the use of government programs (when applicable and qualified) and technology partners. 340B is a part of statute written in 1992 with the federal registrar that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The 340B Program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. The hospital started using 340B for retail prescriptions and later it morphed into mix used areas including emergency room, observation status, etc. There are certain hospitals that qualify and one of the criteria is it has to be non-profit, the drugs are intended for outpatient use. The second criterion requires that the hospital have a sufficient Medicare disproportionate share hospital (DSH) adjustment percentage. DSH hospitals must have an adjustment percentage greater than 11.75 percent for the most recent cost reporting period ending before the calendar quarter involved. Sole community hospitals and Rural referral centers must have an adjustment percentage of greater than 8 percent. Connect with Rita Baskett: On LinkedIn: https://www.linkedin.com/in/rita-bask... Email : rita.baskett@ipsconsultants.com Website: ipsconsults.com Connect with us: Website: http://www.darshantalks.com Law Firm: http://www.kulkarnilawfirm.com Twitter: https://twitter.com/darshantalks LinkedIn: https://www.linkedin.com/in/darshanku... ---- Disclaimers: 1. This discussion is merely an oral discussion and should not be relied upon solely on its own to support any conclusion of law or fact. 2. The discussion does not and should not reflect any individual products status as safe, efficacious, adulterated, or misbranded or meeting or not meeting expectations at a local, state, federal, or international agency or organization. 3. The discussion should not be construed to be complete advice that is right for you and may not necessarily represent a specific product. 4. This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice, or medical advice. 5. This does not create an attorney-client relationship #pharma #340B #darshantalks #hospital #federal Learn more about your ad choices. Visit megaphone.fm/adchoices